Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
- 30 June 2009
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 113 (3), 370-373
- https://doi.org/10.1016/j.ygyno.2008.12.021
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Functional characterization of PIK3CA as a breast cancer oncogene Review of: 1. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells 2. The oncogenic properties of mutant p110 alpha and p110 beta phosphatidylinositol 3-kinases in human mammary epithelial cellsBreast Cancer Online, 2006
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- Uterine Papillary Serous Carcinoma (UPSC): A Clinicopathologic Study of 30 CasesGynecologic Oncology, 1995